Timber pharmaceuticals announces publication of sub-analysis of phase 2b control study in clinical and experimental dermatology

- treatment with tmb-001 demonstrated greater proportions of participants achieving primary and key secondary endpoints versus vehicle regardless of the subtype of congenital ichthyosis -

TMBR Ratings Summary

TMBR Quant Ranking